Prof. Dr. Martin Früh
Medizinische Onkologie und Hämatologie · Dept. I
Immune-checkpoint inhibitors associated with interstitial lung disease in cancer patients
Delaunay M, Campana M, Gautschi O, Früh M, Fumet J, Audigier-Valette C, Couraud S, Dalle S, Leccia M, Jaffro M, Collot S, Prévot G, Milia J, Pérol M, Dansin E, Cadranel J, Lusque A, Meyer N, Gounant V, Moro-Sibilot D, Michot J, Raimbourg J, Girard N, Guisier F, Planchard D, Metivier A, Tomasini P, Mazières J. Immune-checkpoint inhibitors associated with interstitial lung disease in cancer patients. Eur Respir J. 2017; 50
Aug 10, 2017Immune-checkpoint inhibitors associated with interstitial lung disease in cancer patients
Aug 10, 2017Eur Respir J. 2017; 50
Delaunay Myriam, Campana Marion, Gautschi Oliver, Früh Martin, Fumet Jean-David, Audigier-Valette Clarisse, Couraud Sébastien, Dalle Stéphane, Leccia Marie-Thérèse, Jaffro Marion, Collot Samia, Prévot Grégoire, Milia Julie, Pérol Maurice, Dansin Eric, Cadranel Jacques, Lusque Amélie, Meyer Nicolas, Gounant Valérie, Moro-Sibilot Denis, Michot Jean-Marie, Raimbourg Judith, Girard Nicolas, Guisier Florian, Planchard David, Metivier Anne-Cécile, Tomasini Pascale, Mazières Julien
Neutrophil-to-Lymphocyte ratio (NLR) and Platelet-to-Lymphocyte ratio (PLR) as prognostic markers in patients with non-small cell lung cancer (NSCLC) treated with nivolumab
Diem S, Schmid S, Krapf M, Flatz L, Born D, Jochum W, Templeton A, Früh M. Neutrophil-to-Lymphocyte ratio (NLR) and Platelet-to-Lymphocyte ratio (PLR) as prognostic markers in patients with non-small cell lung cancer (NSCLC) treated with nivolumab. Lung Cancer 2017; 111:176-181.
Jul 24, 2017Neutrophil-to-Lymphocyte ratio (NLR) and Platelet-to-Lymphocyte ratio (PLR) as prognostic markers in patients with non-small cell lung cancer (NSCLC) treated with nivolumab
Jul 24, 2017Lung Cancer 2017; 111:176-181
Diem Stefan, Schmid Sabine, Krapf Mirjam, Flatz Lukas, Born Diana, Jochum Wolfram, Templeton Arnoud J, Früh Martin
Role of Cytochrome P450 3A4 and 1A2 Phenotyping in Patients with Advanced Non-small-Cell Lung Cancer Receiving Erlotinib Treatment
Parra-Guillen Z, Kloft C, Krähenbühl S, Gillessen Sommer S, Früh M, Pfister B, Winogradova D, Donzelli M, Haschke M, Berger P, Jörger M. Role of Cytochrome P450 3A4 and 1A2 Phenotyping in Patients with Advanced Non-small-Cell Lung Cancer Receiving Erlotinib Treatment. Basic Clin Pharmacol Toxicol 2017; 121:309-315.
Jun 19, 2017Role of Cytochrome P450 3A4 and 1A2 Phenotyping in Patients with Advanced Non-small-Cell Lung Cancer Receiving Erlotinib Treatment
Jun 19, 2017Basic Clin Pharmacol Toxicol 2017; 121:309-315
Parra-Guillen Zinnia P, Kloft Charlotte, Krähenbühl Stephan, Gillessen Sommer Silke, Früh Martin, Pfister Bogumila, Winogradova Daria, Donzelli Massimiliano, Haschke Manuel, Berger Peter B, Jörger Markus
Phase II Trial of Atezolizumab As First-Line or Subsequent Therapy for Patients With Programmed Death-Ligand 1-Selected Advanced Non-Small-Cell Lung Cancer (BIRCH)
Peters S, van den Heuvel M, Rothenstein J, Reck M, Paz-Ares L, Shepherd F, Kurata T, Li Z, Qiu J, Kowanetz M, Mocci S, Shankar G, Sandler A, Früh M, Ho C, Gettinger S, Johnson M, Jänne P, Garassino M, Christoph D, Toh C, Rizvi N, Chaft J, Carcereny Costa E, Patel J, Chow L, Koczywas M, Felip E. Phase II Trial of Atezolizumab As First-Line or Subsequent Therapy for Patients With Programmed Death-Ligand 1-Selected Advanced Non-Small-Cell Lung Cancer (BIRCH). J Clin Oncol 2017; 35:2781-2789.
Jun 13, 2017Phase II Trial of Atezolizumab As First-Line or Subsequent Therapy for Patients With Programmed Death-Ligand 1-Selected Advanced Non-Small-Cell Lung Cancer (BIRCH)
Jun 13, 2017J Clin Oncol 2017; 35:2781-2789
Peters Solange, van den Heuvel Michel, Rothenstein Jeffrey, Reck Martin, Paz-Ares Luis, Shepherd Frances A, Kurata Takayasu, Li Zhengrong, Qiu Jiaheng, Kowanetz Marcin, Mocci Simonetta, Shankar Geetha, Sandler Alan, Früh Martin, Ho Cheryl, Gettinger Scott, Johnson Melissa L, Jänne Pasi A, Garassino Marina C, Christoph Daniel, Toh Chee Keong, Rizvi Naiyer A, Chaft Jamie E, Carcereny Costa Enric, Patel Jyoti D, Chow Laura Q M, Koczywas Marianna, Felip Enriqueta
Multicenter Phase II Study of Panitumumab in Platinum Pretreated, Advanced Head and Neck Squamous Cell Cancer
Siano M, Frattini M, Ghielmini M, Corradino I, Freguia S, Früh M, Mach N, Martin V, Molinari F, Espeli V. Multicenter Phase II Study of Panitumumab in Platinum Pretreated, Advanced Head and Neck Squamous Cell Cancer. Oncologist 2017
Jun 7, 2017Multicenter Phase II Study of Panitumumab in Platinum Pretreated, Advanced Head and Neck Squamous Cell Cancer
Jun 7, 2017Oncologist 2017
Siano Marco, Frattini Milo, Ghielmini Michele, Corradino Irene, Freguia Stefania, Früh Martin, Mach Nicolas, Martin Vittoria, Molinari Francesca, Espeli Vittoria
Epidermal growth factor receptor and anaplastic lymphoma kinase testing and mutation prevalence in patients with advanced non-small cell lung cancer in Switzerland: A comprehensive evaluation of real world practices
Ess S, Herrmann C, Frick H, Krapf M, Cerny T, Jochum W, Früh M. Epidermal growth factor receptor and anaplastic lymphoma kinase testing and mutation prevalence in patients with advanced non-small cell lung cancer in Switzerland: A comprehensive evaluation of real world practices. Eur J Cancer Care (Engl) 2017
May 30, 2017Epidermal growth factor receptor and anaplastic lymphoma kinase testing and mutation prevalence in patients with advanced non-small cell lung cancer in Switzerland: A comprehensive evaluation of real world practices
May 30, 2017Eur J Cancer Care (Engl) 2017
Ess S M, Herrmann C, Frick H, Krapf M, Cerny T, Jochum Wolfram, Früh Martin
Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF): an international, multicentre, single-arm, phase 2 trial
Rosell R, Shah R, Porta R, Majem M, Gómez-Codina J, Camps C, Thomas M, Rauch D, Barlesi F, Hanrahan E, Kammler R, Stahel R, Molina-Vila M, Shames D, Tam R, Karachaliou N, Kassapian M, Rabaglio M, Ruepp B, Coate L, Puente J, Aix S, Palmero R, Massutí B, Peters S, Gautschi O, Curioni-Fontecedro A, Felip E, Dafni U, Carcereny E, Früh M, Reguart N, Froesch P, Favaretto A, Bidoli P, Cuffe S, Kotsakis A, Popat S, Pless M, BELIEF collaborative group. Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF): an international, multicentre, single-arm, phase 2 trial. Lancet Respir Med 2017; 5:435-444.
Apr 10, 2017Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF): an international, multicentre, single-arm, phase 2 trial
Apr 10, 2017Lancet Respir Med 2017; 5:435-444
Rosell Rafael, Shah Riyaz, Porta Rut, Majem Margarita, Gómez-Codina Jose, Camps Carlos, Thomas Michael, Rauch Daniel, Barlesi Fabrice, Hanrahan Emer, Kammler Roswitha, Stahel Rolf A, Molina-Vila Miguel A, Shames David S, Tam Rachel, Karachaliou Niki, Kassapian Marie, Rabaglio Manuela, Ruepp Barbara, Coate Linda, Puente Javier, Aix Santiago Ponce, Palmero Ramon, Massutí Bartomeu, Peters Solange, Gautschi Oliver, Curioni-Fontecedro Alessandra, Felip Enriqueta, Dafni Urania, Carcereny Enric, Früh Martin, Reguart Noemí, Froesch Patrizia, Favaretto Adolfo, Bidoli Paolo, Cuffe Sinead, Kotsakis Athanasios, Popat Sanjay, Pless Miklos, BELIEF collaborative group
24h-gene variation effect of combined bevacizumab/erlotinib in advanced non-squamous non-small cell lung cancer using exon array blood profiling
Baty F, Jörger M, Früh M, Klingbiel D, Zappa F, Brutsche M. 24h-gene variation effect of combined bevacizumab/erlotinib in advanced non-squamous non-small cell lung cancer using exon array blood profiling. J Transl Med 2017; 15:66.
Mar 30, 201724h-gene variation effect of combined bevacizumab/erlotinib in advanced non-squamous non-small cell lung cancer using exon array blood profiling
Mar 30, 2017J Transl Med 2017; 15:66
Baty Florent, Jörger Markus, Früh Martin, Klingbiel Dirk, Zappa Francesco, Brutsche Martin
Targeting RET in Patients With RET-Rearranged Lung Cancers: Results From the Global, Multicenter RET Registry
Drilon A, Früh M, Diebold J, Zeidler K, Velcheti V, Riess J, Gandara D, Zalcman G, Froesch P, Michels S, Monnet I, Popat S, Mazières J, Cabillic F, Muley T, Warth A, Shih J, Rothschild S, Karachaliou N, Rosell R, Pall G, Ou S, Yang J, Doebele R, Narayanan V, Camidge R, Owen D, Carbone D, Wolf J, Filleron T, Milia J, Besse B, Remon-Masip J, Jänne P, Mok T, Neal J, Wakelee H, Van Den Heuvel M, Karp D, Byoung C, Peled N, Awad M, Gautschi O. Targeting RET in Patients With RET-Rearranged Lung Cancers: Results From the Global, Multicenter RET Registry. J Clin Oncol 2017; 35:1403-1410.
Mar 13, 2017Targeting RET in Patients With RET-Rearranged Lung Cancers: Results From the Global, Multicenter RET Registry
Mar 13, 2017J Clin Oncol 2017; 35:1403-1410
Drilon Alexander, Früh Martin, Diebold Joachim, Zeidler Kristin, Velcheti Vamsidhar, Riess Jonathan W, Gandara David R, Zalcman Gérard, Froesch Patrizia, Michels Sebastian, Monnet Isabelle, Popat Sanjay, Mazières Julien, Cabillic Florian, Muley Thomas, Warth Arne, Shih Jin-Yuan, Rothschild Sacha I, Karachaliou Niki, Rosell Rafael, Pall Georg, Ou Sai-Hong Ignatius, Yang James C H, Doebele Robert C, Narayanan Vignhesh, Camidge Ross, Owen Dwight, Carbone David P, Wolf Juergen, Filleron Thomas, Milia Julie, Besse Benjamin, Remon-Masip Jordi, Jänne Pasi A, Mok Tony S K, Neal Joel W, Wakelee Heather A, Van Den Heuvel Michael, Karp Daniel D, Byoung Chul-Cho, Peled Nir, Awad Mark M, Gautschi Oliver
Clinical Outcome of ALK-Positive Non-Small Cell Lung Cancer (NSCLC) Patients with De Novo EGFR or KRAS Co-Mutations Receiving Tyrosine Kinase Inhibitors (TKIs)
Schmid S, Diebold J, Jochum W, Reichegger H, Klingbiel D, Froesch P, Mark M, Rothschild S, Gautschi O, Früh M. Clinical Outcome of ALK-Positive Non-Small Cell Lung Cancer (NSCLC) Patients with De Novo EGFR or KRAS Co-Mutations Receiving Tyrosine Kinase Inhibitors (TKIs). J Thorac Oncol 2016
Dec 19, 2016Clinical Outcome of ALK-Positive Non-Small Cell Lung Cancer (NSCLC) Patients with De Novo EGFR or KRAS Co-Mutations Receiving Tyrosine Kinase Inhibitors (TKIs)
Dec 19, 2016J Thorac Oncol 2016
Schmid Sabine, Diebold Joachim, Jochum Wolfram, Reichegger Hermann, Klingbiel Dirk, Froesch Patrizia, Mark Michael, Rothschild Sacha, Gautschi Oliver, Früh Martin
Bevacizumab Plus Pemetrexed Versus Pemetrexed Alone as Maintenance Therapy for Patients With Advanced Nonsquamous Non-Small-cell Lung Cancer: Update From the Swiss Group for Clinical Cancer Research (SAKK) 19/09 Trial
Gautschi O, Ochsenbein A, Mach N, Biaggi C, Schneider M, Zander T, Froesch P, Peters S, Pless M, Rauch D, Cathomas R, Stahel R, Früh M, Betticher D, Zippelius A, Matter-Walstra K, Li Q, Rothschild S. Bevacizumab Plus Pemetrexed Versus Pemetrexed Alone as Maintenance Therapy for Patients With Advanced Nonsquamous Non-Small-cell Lung Cancer: Update From the Swiss Group for Clinical Cancer Research (SAKK) 19/09 Trial. Clin Lung Cancer 2016
Nov 23, 2016Bevacizumab Plus Pemetrexed Versus Pemetrexed Alone as Maintenance Therapy for Patients With Advanced Nonsquamous Non-Small-cell Lung Cancer: Update From the Swiss Group for Clinical Cancer Research (SAKK) 19/09 Trial
Nov 23, 2016Clin Lung Cancer 2016
Gautschi Oliver, Ochsenbein Adrian F, Mach Nicolas, Biaggi Christine, Schneider Martina, Zander Thilo, Froesch Patrizia, Peters Solange, Pless Miklos, Rauch Daniel, Cathomas Richard, Stahel Rolf A, Früh Martin, Betticher Daniel C, Zippelius Alfred, Matter-Walstra Klazien, Li Qiyu, Rothschild Sacha I
SUVmax and Tumour Location in PET-CT Predict Oncogene Status in Lung Cancer
Putora P, Szentesi K, Glatzer M, Rodriguez R, Müller J, Baty F, Früh M. SUVmax and Tumour Location in PET-CT Predict Oncogene Status in Lung Cancer. Oncol Res Treat 2016; 39:681-686.
Oct 19, 2016SUVmax and Tumour Location in PET-CT Predict Oncogene Status in Lung Cancer
Oct 19, 2016Oncol Res Treat 2016; 39:681-686
Putora Paul Martin, Szentesi Kinga, Glatzer Markus, Rodriguez Regulo, Müller Joachim, Baty Florent, Früh Martin
Characterization of nivolumab-associated skin reactions in patients with metastatic non-small cell lung cancer
Hasan Ali O, Diem S, Markert E, Jochum W, Kerl K, French L, Speiser D, Früh M, Flatz L. Characterization of nivolumab-associated skin reactions in patients with metastatic non-small cell lung cancer. Oncoimmunology 2016; 5:e1231292.
Sep 19, 2016Characterization of nivolumab-associated skin reactions in patients with metastatic non-small cell lung cancer
Sep 19, 2016Oncoimmunology 2016; 5:e1231292
Hasan Ali Omar, Diem Stefan, Markert Eva, Jochum Wolfram, Kerl Katrin, French Lars E, Speiser Daniel E, Früh Martin, Flatz Lukas
Pembrolizumab-associated minimal change disease in a patient with malignant pleural mesothelioma
Bickel A, Koneth I, Enzler-Tschudy A, Neuweiler J, Flatz L, Früh M. Pembrolizumab-associated minimal change disease in a patient with malignant pleural mesothelioma. BMC cancer 2016; 16:656.
Aug 19, 2016Pembrolizumab-associated minimal change disease in a patient with malignant pleural mesothelioma
Aug 19, 2016BMC cancer 2016; 16:656
Bickel Angelika, Koneth Irene, Enzler-Tschudy Annette, Neuweiler Jörg, Flatz Lukas, Früh Martin
Erlotinib has comparable clinical efficacy to chemotherapy in pretreated patients with advanced non-small cell lung cancer (NSCLC): A propensity-adjusted, outcomes research-based study
Neumair P, Cerny T, Krähenbühl S, Baty F, Brutsche M, Früh M, Hitz F, Ess S, Dutly A, Warschkow R, Joos L, Jörger M. Erlotinib has comparable clinical efficacy to chemotherapy in pretreated patients with advanced non-small cell lung cancer (NSCLC): A propensity-adjusted, outcomes research-based study. Lung Cancer 2016; 100:38-44.
Jul 28, 2016Erlotinib has comparable clinical efficacy to chemotherapy in pretreated patients with advanced non-small cell lung cancer (NSCLC): A propensity-adjusted, outcomes research-based study
Jul 28, 2016Lung Cancer 2016; 100:38-44
Neumair P, Cerny Thomas, Krähenbühl S, Baty Florent, Brutsche Martin, Früh Martin, Hitz Felicitas, Ess S, Dutly A, Warschkow Rene, Joos L, Jörger Markus
Preoperative chemoradiotherapy with cisplatin and docetaxel for stage IIIB non-small-cell lung cancer: 10-year follow-up of the SAKK 16/01 trial
Früh M, Ris H, Xyrafas A, Peters S, Mirimanoff R, Gautschi O, Pless M, Stupp R. Preoperative chemoradiotherapy with cisplatin and docetaxel for stage IIIB non-small-cell lung cancer: 10-year follow-up of the SAKK 16/01 trial. Ann Oncol 2016; 27:1971-3.
Jun 29, 2016Preoperative chemoradiotherapy with cisplatin and docetaxel for stage IIIB non-small-cell lung cancer: 10-year follow-up of the SAKK 16/01 trial
Jun 29, 2016Ann Oncol 2016; 27:1971-3
Früh Martin, Ris H B, Xyrafas A, Peters S, Mirimanoff R O, Gautschi O, Pless M, Stupp R
Rapid Intracranial Response to Osimertinib in a Patient with Epidermal Growth Factor Receptor T790M-Positive Adenocarcinoma of the Lung
Reichegger H, Jochum W, Förbs D, Hader C, Früh M. Rapid Intracranial Response to Osimertinib in a Patient with Epidermal Growth Factor Receptor T790M-Positive Adenocarcinoma of the Lung. Oncol Res Treat 2016; 39:461-3.
Jun 15, 2016Rapid Intracranial Response to Osimertinib in a Patient with Epidermal Growth Factor Receptor T790M-Positive Adenocarcinoma of the Lung
Jun 15, 2016Oncol Res Treat 2016; 39:461-3
Reichegger Hermann, Jochum Wolfram, Förbs Diana, Hader Claudia, Früh Martin
Chemotherapy is not superior to erlotinib in pretreated patients with advanced non-small cell lung cancer (NSCLC): A retrospective study
Neumair P, Krähenbühl S, Baty F, Brutsche M, Früh M, Hitz F, Ess S, Warschkow R, Joos L, Jörger M (2016). Chemotherapy is not superior to erlotinib in pretreated patients with advanced non-small cell lung cancer (NSCLC): A retrospective study - Abstrakt 169P.
Apr 15, 2016Chemotherapy is not superior to erlotinib in pretreated patients with advanced non-small cell lung cancer (NSCLC): A retrospective study
Apr 15, 2016European Lung Cancer Conference
Neumair P, Krähenbühl S, Baty Florent, Brutsche Martin, Früh Martin, Hitz Felicitas, Ess S, Warschkow Rene, Joos L, Jörger Markus
61PD 24h-blood profile gene expression biomarkers of the response to targeted therapy in advanced non-squamous non-small cell lung cancer (NSCLC)
Baty F, Jörger M, Früh M, Brutsche M. 61PD 24h-blood profile gene expression biomarkers of the response to targeted therapy in advanced non-squamous non-small cell lung cancer (NSCLC). J Thorac Oncol 2016; 11:S81.
Apr 15, 201661PD 24h-blood profile gene expression biomarkers of the response to targeted therapy in advanced non-squamous non-small cell lung cancer (NSCLC)
Apr 15, 2016J Thorac Oncol 2016; 11:S81
Baty Florent, Jörger Markus, Früh Martin, Brutsche Martin
Lung cancer patients with HER2 mutations treated with chemotherapy and HER2-targeted drugs: results from the European EUHER2 cohort
Mazières J, Milia J, Moro-Sibilot D, Cortot A, Cappuzzo F, Westeel V, Fournel P, Wislez M, Rosell R, Pless M, Früh M, Dansin E, Peters S, Beau-Faller M, Monnet I, Besse B, Filleron T, Barlesi F, Gautschi O. Lung cancer patients with HER2 mutations treated with chemotherapy and HER2-targeted drugs: results from the European EUHER2 cohort. Ann Oncol 2015; 27:281-6.
Nov 23, 2015Lung cancer patients with HER2 mutations treated with chemotherapy and HER2-targeted drugs: results from the European EUHER2 cohort
Nov 23, 2015Ann Oncol 2015; 27:281-6
Mazières J, Milia J, Moro-Sibilot D, Cortot A, Cappuzzo F, Westeel V, Fournel P, Wislez M, Rosell R, Pless M, Früh Martin, Dansin E, Peters S, Beau-Faller M, Monnet I, Besse B, Filleron T, Barlesi F, Gautschi O